Resveratrol for Stage IV Cancer
Also known as: trans-Resveratrol
Resveratrol's anti-proliferative and apoptotic effects span multiple cancer pathways, making it a studied adjunctive agent.
Mechanism of Action
In cancer, resveratrol inhibits NF-κB and STAT3 survival signaling, induces cell cycle arrest (G1/S phase), promotes apoptosis through p53 activation and Bax/Bcl-2 ratio modulation, and inhibits angiogenesis. It also sensitizes cancer cells to chemotherapy and radiation through multiple mechanisms.
General mechanism: Stilbenoid polyphenol. SIRT1 activator, NF-κB inhibitor, PGC-1α inducer, antioxidant. Multiple anti-aging and anti-cancer targets.
Current Evidence
Extensive preclinical evidence. Limited clinical data due to rapid metabolism and low bioavailability. Some Phase I studies show safety in cancer patients. Combination studies with standard therapies ongoing.
Clinical Status: Phase I/II in various cancers. Bioavailability limitations. Available as supplement.
Safety Profile
Very safe. GI effects at high doses. Rapid metabolism limits bioavailability. May interact with anticoagulants.
Key Research Questions
- Can resveratrol enhance chemotherapy efficacy through NF-κB suppression?
- What formulation strategy overcomes the rapid glucuronidation problem?